News
NPCE
11.14
-2.62%
-0.30
NeuroPace (NPCE) Upgraded to Buy: What Does It Mean for the Stock?
NASDAQ · 20h ago
Weekly Report: what happened at NPCE last week (1216-1220)?
Weekly Report · 3d ago
Positive Outlook for NeuroPace: Anticipated Success of NAUTILUS Study and Strategic Market Advantage
TipRanks · 5d ago
NeuroPace, Inc. to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
Barchart · 12/19 01:24
NeuroPace Is Maintained at Overweight by JP Morgan
Dow Jones · 12/17 17:32
NeuroPace Price Target Raised to $14.00/Share From $9.00 by JP Morgan
Dow Jones · 12/17 17:32
JP Morgan Maintains Overweight on NeuroPace, Raises Price Target to $14
Benzinga · 12/17 17:21
NeuroPace: Undervalued Innovator in the Drug-Resistant Epilepsy Market with Promising Long-Term Growth
TipRanks · 12/17 10:37
NeuroPace price target raised to $14 from $9 at JPMorgan
TipRanks · 12/17 10:35
Weekly Report: what happened at NPCE last week (1209-1213)?
Weekly Report · 12/16 12:14
NeuroPace, Inc. Announces Investor Day to Discuss RNS Technology and Future Plans on January 28, 2025
Barchart · 12/13 01:24
NeuroPace to Host Investor Day on January 28th in New York City
Barchart · 12/12 15:05
NeuroOne Medical Technologies: A Small-Cap Electrode Technology Play With Multiple Catalysts Ahead
Seeking Alpha · 12/10 08:15
Weekly Report: what happened at NPCE last week (1202-1206)?
Weekly Report · 12/09 12:13
Wall Street Analysts Think NeuroPace (NPCE) Could Surge 31.47%: Read This Before Placing a Bet
NASDAQ · 12/06 14:55
Lake Street Sticks to Its Buy Rating for NeuroPace (NPCE)
TipRanks · 12/05 16:58
NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting
Barchart · 12/04 15:05
NeuroPace, Inc. Completes Enrollment in Feasibility Study for RNS® System in Treating Lennox-Gastaut Syndrome
Barchart · 12/04 01:20
NeuroPace Completes Enrollment In Feasibility Study Of RNS System For Lennox-Gastaut Syndrome; Received A $9.3M National Institutes Of Health Grant Through The Brain Research Through Advancing Innovative Neurotechnologies Initiative To Evaluate Its Responsive Neuromodulation Technology In Those Who Suffer From LGS
Benzinga · 12/03 21:16
NeuroPace completes enrollment in RNS System IDE study
TipRanks · 12/03 21:10
More
Webull provides a variety of real-time NPCE stock news. You can receive the latest news about Neuropace Inc through multiple platforms. This information may help you make smarter investment decisions.
About NPCE
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.